Published in Am J Physiol Cell Physiol on July 29, 2015
The added value of circulating tumor cells examination in ovarian cancer staging. Am J Cancer Res (2015) 0.83
Targeting Stromal-Cancer Cell Crosstalk Networks in Ovarian Cancer Treatment. Biomolecules (2016) 0.80
Migration and invasion is inhibited by silencing ROR1 and ROR2 in chemoresistant ovarian cancer. Oncogenesis (2016) 0.80
Prognostic significance of discoidin domain receptor 2 (DDR2) expression in ovarian cancer. Am J Transl Res (2016) 0.75
HBXIP overexpression is correlated with the clinical features and survival outcome of ovarian cancer. J Ovarian Res (2017) 0.75
Overexpression of TRIM24 is correlated with the progression of human cervical cancer. Am J Transl Res (2017) 0.75
Cell and Molecular Processes in Cancer Metastasis: an AJP-Cell Physiology set of Themed Reviews. Am J Physiol Cell Physiol (2015) 0.75
Antitumor properties of Coenzyme Q0 against human ovarian carcinoma cells via induction of ROS-mediated apoptosis and cytoprotective autophagy. Sci Rep (2017) 0.75
Cancer statistics, 2015. CA Cancer J Clin (2015) 57.51
Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med (2003) 35.39
Cellular motility driven by assembly and disassembly of actin filaments. Cell (2003) 26.05
New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer (2002) 24.71
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell (1996) 23.99
Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science (2005) 23.44
Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet (2008) 20.62
Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer (2002) 17.49
Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer (2009) 14.17
Molecular mechanisms and clinical applications of angiogenesis. Nature (2011) 13.36
The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev (1989) 13.15
VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol (2006) 12.09
Cancer and the chemokine network. Nat Rev Cancer (2004) 10.27
Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer (2004) 9.68
The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer (2009) 9.01
Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med (2011) 8.93
A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med (2011) 8.63
Cell migration: Rho GTPases lead the way. Dev Biol (2004) 8.20
Sunitinib: from rational design to clinical efficacy. J Clin Oncol (2007) 7.26
Tumor stroma and regulation of cancer development. Annu Rev Pathol (2006) 6.66
Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med (2011) 6.15
Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci U S A (2003) 6.06
Ovarian cancer development and metastasis. Am J Pathol (2010) 5.92
Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell (2014) 5.87
Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell (2014) 5.38
The role of angiogenesis in tumor growth. Semin Cancer Biol (1992) 5.33
The many faces of actin: matching assembly factors with cellular structures. Nat Cell Biol (2007) 4.90
Forming functional fat: a growing understanding of adipocyte differentiation. Nat Rev Mol Cell Biol (2011) 4.72
Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle (2006) 4.67
AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res (2005) 4.21
Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther (2006) 4.20
Regulation of cancer cell motility through actin reorganization. Cancer Sci (2005) 3.87
Mechanisms of myofibroblast activity and phenotypic modulation. Exp Cell Res (1999) 3.78
Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med (2008) 3.35
Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat Rev Cancer (2005) 3.20
Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochim Biophys Acta (1990) 3.18
Ovarian carcinoma diagnosis. Cancer (2000) 3.12
Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol (2014) 3.05
Therapeutic targeting of the tumor microenvironment. Cancer Cell (2005) 2.86
Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion. Cancer Res (2011) 2.85
The actin cytoskeleton in cancer cell motility. Clin Exp Metastasis (2008) 2.82
Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol (2005) 2.81
Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J Natl Cancer Inst (2002) 2.75
In vivo fate of the inflammatory macrophage during the resolution of inflammation: inflammatory macrophages do not die locally, but emigrate to the draining lymph nodes. J Immunol (1996) 2.74
VEGF targets the tumour cell. Nat Rev Cancer (2013) 2.71
Absence of CC chemokine ligand 2 does not limit obesity-associated infiltration of macrophages into adipose tissue. Diabetes (2007) 2.54
Tropomyosin isoforms: divining rods for actin cytoskeleton function. Trends Cell Biol (2005) 2.45
Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res (2005) 2.37
Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum. Int J Cancer (2007) 2.31
Calcium in tumour metastasis: new roles for known actors. Nat Rev Cancer (2011) 2.30
The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest (2008) 2.24
Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Res (1995) 2.24
Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochim Biophys Acta (2002) 2.18
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol (2014) 2.18
Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer (1999) 2.17
Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin Cancer Res (2012) 2.16
Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res (2003) 2.14
Tumor microenvironment complexity: emerging roles in cancer therapy. Cancer Res (2012) 2.09
Calcium gradients underlying polarization and chemotaxis of eosinophils. Science (1991) 2.08
Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol (2006) 2.06
Crawling toward a unified model of cell mobility: spatial and temporal regulation of actin dynamics. Annu Rev Biochem (2004) 1.95
Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol (1998) 1.90
Force transmission in migrating cells. J Cell Biol (2010) 1.89
A novel platform for detection of CK+ and CK- CTCs. Cancer Discov (2011) 1.88
Mechanisms of human tumor metastasis studied in patients with peritoneovenous shunts. Cancer Res (1984) 1.88
Adipose tissue and adipocytes support tumorigenesis and metastasis. Biochim Biophys Acta (2013) 1.85
The clinical significance of hepatic parenchymal metastasis in patients with primary epithelial ovarian cancer. Gynecol Oncol (2008) 1.81
Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas. J Clin Oncol (2007) 1.80
Differential gene expression in ovarian carcinoma: identification of potential biomarkers. Am J Pathol (2004) 1.79
CXCL8/IL-8 and CXCL12/SDF-1alpha co-operatively promote invasiveness and angiogenesis in pancreatic cancer. Int J Cancer (2009) 1.79
Tumour-stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy? Lung Cancer (2004) 1.78
Molecular mechanisms of angiogenesis: fibroblast growth factor signal transduction. FASEB J (1995) 1.76
Invadopodia and podosomes in tumor invasion. Eur J Cell Biol (2005) 1.75
Inhibition of angiogenesis. Semin Cancer Biol (1992) 1.72
Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma. Am J Pathol (2002) 1.70
Gene expression patterns that characterize advanced stage serous ovarian cancers. J Soc Gynecol Investig (2004) 1.68
Ovarian cancer: can we make the clinical diagnosis earlier? Cancer (2005) 1.63
Ascitic fluid analysis in malignancy-related ascites. Hepatology (1988) 1.62
Preferential attachment of peritoneal tumor metastases to omental immune aggregates and possible role of a unique vascular microenvironment in metastatic survival and growth. Am J Pathol (2006) 1.61
Patterns of elevated free calcium and calmodulin activation in living cells. Nature (1992) 1.58
TGF-β modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment. Cancer Res (2013) 1.56
Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer. Neoplasia (2011) 1.56
Mature adipocytes, but not preadipocytes, promote the growth of breast carcinoma cells in collagen gel matrix culture through cancer-stromal cell interactions. J Pathol (2003) 1.56
Optical quantification of cellular mass, volume, and density of circulating tumor cells identified in an ovarian cancer patient. Front Oncol (2012) 1.54
E-cadherin expression in human epithelial ovarian cancer and normal ovary. Int J Cancer (1997) 1.51
Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice. Cancer Res (2007) 1.50
Predicting biomarkers for ovarian cancer using gene-expression microarrays. Br J Cancer (2004) 1.47
Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells. Cancer Res (2001) 1.45
Cell-cell adhesion in the normal ovary and ovarian tumors of epithelial origin; an exception to the rule. Mol Cell Endocrinol (2003) 1.45
In vivo inhibition of CD44 limits intra-abdominal spread of a human ovarian cancer xenograft in nude mice: a novel role for CD44 in the process of peritoneal implantation. Cancer Res (1997) 1.42
Pazopanib: Clinical development of a potent anti-angiogenic drug. Crit Rev Oncol Hematol (2010) 1.36
Lysophosphatidic Acid Stimulates Ovarian Cancer Cell Migration via a Ras-MEK Kinase 1 Pathway. Cancer Res (2004) 1.33
High-resolution analysis of copy number alterations and associated expression changes in ovarian tumors. BMC Med Genomics (2009) 1.33
Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma. Cancer (2004) 1.33
Milky spots as the implantation site for malignant cells in peritoneal dissemination in mice. Cancer Res (1993) 1.32
Possible regulation of migration of intrahepatic cholangiocarcinoma cells by interaction of CXCR4 expressed in carcinoma cells with tumor necrosis factor-alpha and stromal-derived factor-1 released in stroma. Am J Pathol (2006) 1.31
The peritoneal ligaments and mesenteries: pathways of intraabdominal spread of disease. Radiology (1987) 1.30
Intraperitoneal cancer dissemination: mechanisms of the patterns of spread. Cancer Metastasis Rev (2003) 1.28
Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Int J Oncol (2000) 1.28